Clinical trial ANAM-17-21
A phase 3, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of Anamorelin HCL for the treatment of malignancy associated weight loss and anorexia in adult patients with advanced nonsmall cell lung cancer (NSCLC)
| Cancers | |
|---|---|
| Organ | NSCLC |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Helsinn Healthcare SA |
| EudraCT Identifier | 2018-002927-40 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT03743064 |
| Inclusion criteria | Ongoing problemn with apetite/eating. Maximum 3 lines of systemic prior |
| Last update |